Why the study?
This study aimed to elucidate the mechanism of action and impact of the Xuanshen Yishen Mixture on hypertension.
Does Xuanshen Yishen mixture reduce blood pressure in patients with grade 1 essential hypertension?
Does Xuanshen Yishen mixture reduce blood pressure in patients with grade 1 essential hypertension?
Answers are grounded in this paper and cite their sources.
Xuanshen Yishen mixture demonstrated comparable blood pressure-lowering efficacy to valsartan in a small retrospective cohort of patients with grade 1 essential hypertension, supported by network pharmacology identifying multiple potential therapeutic targets.
OBJECTIVE: This study aims to elucidate the mechanism of action and impact of the "Xuanshen Yishen Mixture" (XYM) on hypertension. METHODS: Active components were identified and potential targets were predicted using the Traditional Chinese Medicine Systems Pharmacology database. Hypertension-related targets were collected from GeneCards, DRUGBANK, OMIM, TTD, and PharmaGKB databases. Intersections of disease and drug targets were visualized using the R package "VennDiagram". A protein-protein interaction network was established via the STRING database. GO function enrichment and KEGG pathway analyses were conducted using "clusterProfiler", while "Cytoscape" was used to construct a "drug-component-target" network. Additionally, data from 60 patients with essential hypertension from the Affiliated Hospital of Shandong University of Traditional Chinese Medicine were retrospectively analyzed. Patients were divided into a control group (n = 30) and an XYM group (n = 30) based on treatment regimen. RESULTS: Sixty active ingredients and 98 related targets were identified from Uncaria, Radix Scrophulariae, and Epimedium in hypertension treatment. Key active components such as quercetin, kaempferol, yohimbine, and beta-sitosterol were pinpointed, with PTGS2, PTGS1, AR, DPP4, and F2 as crucial targets. KEGG pathway analysis highlighted significant pathways including IL-17 signaling, TNF signaling, Relaxin signaling, and HIF-1 signaling. Clinical data indicated that XYM's therapeutic effects are comparable to those of valsartan, which significantly reduced diastolic and systolic blood pressure and demonstrated good biosafety. CONCLUSIONS: Uncaria, Radix Scrophulariae, and Epimedium effectively mitigate hypertension through multiple components, targets, and pathways. Additionally, DPP4, IL-17, and TNF-α are identified as potential therapeutic targets for traditional Chinese medicine preparations in hypertension treatment. This study provides a foundation for further investigation into XYM's mechanisms in hypertension management.
No takes yet. Share an insight, caveat, or question.
Haiyan Wang (2024) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: